Top Markets
Coin of the day
ObsEva S.A. ObsEva S.A.

ObsEva S.A.

OBSN
株式のランク #40302
ObsEva S.A. is a biopharmaceutical company focused on developing and... ObsEva S.A. is a biopharmaceutical company focused on developing and commercializing groundbreaking therapies for women facing challenges in reproductive health and pregnancy. Its product pipeline includes Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist currently in Phase III clinical trials. Linzagolix is being evaluated for its efficacy in treating pain associated with endometriosis and heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. The firm is also progressing with Ebopiprant, an oral and selective prostaglandin F2a (PGF2a) receptor antagonist, which is in Phase II clinical trials as a once-daily treatment for preterm labor occurring between 24 and 34 weeks of gestational age. Additionally, ObsEva is developing Nolasiban, an oral oxytocin receptor antagonist in Phase I clinical trials, aimed at enhancing clinical pregnancy and live birth rates for women undergoing in vitro fertilization. ObsEva S.A. was founded in 2012 and maintains its headquarters in Geneva, Switzerland.
株価
$0.00156067
最終同期: 2024-05-03
時価総額
$182.87K
変化(1日)
-72.69%
変化(1年)
0.00%
CH
取引 ObsEva S.A. (OBSN)

カテゴリー

ObsEva S.A.(OBSN)の株式分割履歴
ObsEva S.A.株(シンボル:OBSN)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 14, 2026に行われました。
Aug 14, 2026より前に購入されたOBSN株は、現在0OBSN株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE